Standardization of the methods and reference materials used to assess virus content in varicella vaccines Herpes viruses

Virology Journal

Volumn 12, Issue 1, 2015, Pages

  Hong, Jiyoung ^a,b   Oh, Ho Jung ^a   Lee, Naery ^a   Kim, Do Keun ^a   Yoon, Heui Seong ^a   Kim, Yeon Tae ^a   Chang, Seokkee ^a   Park, Jae Hak ^b   Chung, Hyejoo ^a  

^a National Institute of Food and Drug Safety Evaluation   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Korean reference material; National Center for Lot Release; Vaccine; Varicella; Virus content

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ACCURACY; AGAR OVERLAY METHOD; ANALYTICAL PARAMETERS; ARTICLE; ASSAY; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DETERMINATION; INTERMETHOD COMPARISON; KOREA; PLAQUE STAININING METHOD; PROCESS DEVELOPMENT; QUALITY CONTROL; RELIABILITY; REPRODUCIBILITY; STANDARDIZATION; VIRUS CONCENTRATION; VIRUS CONTENT; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; MULTICENTER STUDY; PHARMACEUTICS; PROCEDURES; SOUTH KOREA; STANDARDS; VIRAL PLAQUE ASSAY; VIRUS LOAD;

HERPESVIRIDAE;

CHICKENPOX VACCINE; HUMANS; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; TECHNOLOGY, PHARMACEUTICAL; VIRAL LOAD; VIRAL PLAQUE ASSAY;

EID: 84936860017     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-015-0333-1     Document Type: Article

References (14)

1. Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J. 2005;24:434-7.
2. Unim B, Saulle R, Boccalini S, Taddei C, Ceccherini V, Boccia A, et al. Economic evaluation of varicella vaccination (Results of a systematic review). Hum Vaccin Immunother. 2013;9:1932-42.
3. Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955-60.
4. Takahashi M. 25 years' experience with the Biken Oka strain varicella vaccine: a clinical review. Paediatr Drugs. 2001;3:285-92.
5. Quinlivan M, Breuer J. Clinical and molecular aspects of the live attenuated Oka varicella vaccine. Rev Med Virol. 2014;24:254-73.
6. Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis. 2008;197:S185-190.
7. Oh SH, Choi EH, Shin SH, Kim YK, Chang JK, Choi KM, et al. Varicella and varicella vaccination in South Korea. Clin Vaccine Immunol. 2014;21:762-8.
8. Heider H, Schroeder C. Focus luminescence assay: macroscopically visualized foci of human cytomegalovirus and varicella zoster virus infection. J Vriol Methods. 1997;66:311-6.
9. Krah DL, Schofield TL, Provost PL. Enhancement of varicella-zoster virus plaquing efficiency with an agarose overlay medium. J Virol Methods. 1990;27:319-26.
10. Kim JI, Jung GS, Kim YY, Ji GY, Kim HS, Wang WD, et al. Sequencing and characterization of Varicella-Zoster virus vaccine strain Suduvax. Virol J. 2011;8:547.
11. nd national standard for varicella vaccine. Korean Soci Biotech Bioengineer Journal. 2010;25:572-6.
12. Quinlivan M, Breuer J. Molecular studies of varicella zoster virus. Rev Med Virol. 2006;16:225-50.
13. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study. Vaccine. 2014;32:1745-53.
14. HT) in immunocompromised adults. J Infect Dis. 2013;208:1375-85.